{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:27:56Z","timestamp":1787372876266,"version":"build-2736575974"},"reference-count":38,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,8,22]]},"DOI":"10.1248\/bpb.b26-00209","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T22:10:51Z","timestamp":1787350251000},"page":"1276-1284","source":"Crossref","is-referenced-by-count":0,"title":["Association between the Pharmacokinetic Parameters of Ganciclovir and Clinical Efficacy and Safety in the Treatment of Cytomegalovirus Infection"],"prefix":"10.1248","volume":"49","author":[{"given":"Yanika","family":"Roongpairoj","sequence":"first","affiliation":[{"name":"Division of Pharmacy, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Uchida","sequence":"first","affiliation":[{"name":"Division of Pharmacy, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"},{"name":"Graduate School of Pharmaceutical Sciences, Chiba University, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138675, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"},{"name":"Graduate School of Pharmaceutical Sciences, Chiba University, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138675, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Biostatistics Section, Clinical Research Center, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Goto","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"},{"name":"Graduate School of Pharmaceutical Sciences, Chiba University, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138675, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"},{"name":"Graduate School of Pharmaceutical Sciences, Chiba University, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138675, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuko","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Chiba University Hospital, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138677, Japan"},{"name":"Graduate School of Pharmaceutical Sciences, Chiba University, 1\u20138\u20131 Inohana, Chuo-ku, Chiba 260\u20138675, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kotton CN. CMV: prevention, diagnosis and therapy. <i>Am. J. Transplant.<\/i>, <b>13<\/b> (Suppl 3), 24\u201340, quiz, 40 (2013).","DOI":"10.1111\/ajt.12006"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) de la C\u00e1mara R. CMV in hematopoietic stem cell transplantation. <i>Mediterr. J. Hematol. Infect. Dis.<\/i>, <b>8<\/b>, e2016031 (2016).","DOI":"10.4084\/mjhid.2016.031"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. <i>Crit. Care<\/i>, <b>13<\/b>, R68 (2009).","DOI":"10.1186\/cc7875"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin CM. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. <i>Expert Opin. Drug Metab. Toxicol.<\/i>, <b>11<\/b>, 205\u2013219 (2015).","DOI":"10.1517\/17425255.2015.988139"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Franck B, Autmizguine J, Marquet P, Ovetchkine P, Woillard JB. Pharmacokinetics, pharmacodynamics, and therapeutic drug monitoring of valganciclovir and ganciclovir in transplantation. <i>Clin. Pharmacol. Ther.<\/i>, <b>112<\/b>, 233\u2013276 (2022).","DOI":"10.1002\/cpt.2431"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. <i>Clin. Pharmacokinet.<\/i>, <b>48<\/b>, 399\u2013418 (2009).","DOI":"10.2165\/00003088-200948060-00006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Gotta V, Leuppi-Taegtmeyer A, Gessler M, Pfister M, M\u00fcller D, Jehle AW. Intensive hemodiafiltration successfully removes ganciclovir overdose and largely exceeds reported elimination during hemodialysis-a case report and review of the literature. <i>Front. Pharmacol.<\/i>, <b>11<\/b>, 882 (2020).","DOI":"10.3389\/fphar.2020.00882"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. <i>Blood<\/i>, <b>90<\/b>, 2502\u20132508 (1997).","DOI":"10.1182\/blood.V90.6.2502.2502_2502_2508"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Tomonari A, Iseki T, Takahashi S, Ooi J, Yamada T, Takasugi K, Nagamura F, Uchimaru K, Tojo A, Asano S. Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation. <i>Ann. Hematol.<\/i>, <b>83<\/b>, 573\u2013577 (2004).","DOI":"10.1007\/s00277-004-0887-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Matsumoto K, Shigemi A, Ikawa K, Kanazawa N, Fujisaki Y, Morikawa N, Takeda Y. Risk factors for ganciclovir-induced thrombocytopenia and leukopenia. <i>Biol. Pharm. Bull.<\/i>, <b>38<\/b>, 235\u2013238 (2015).","DOI":"10.1248\/bpb.b14-00588"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Zuideveld KP. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. <i>Transplantation<\/i>, <b>79<\/b>, 1477\u20131483 (2005).","DOI":"10.1097\/01.TP.0000164512.99703.AD"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ritchie BM, Barreto JN, Barreto EF, Crow SA, Dierkhising RA, Jannetto PJ, Tosh PK, Razonable RR. Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety. <i>Antimicrob. Agents Chemother.<\/i>, <b>63<\/b>, e01855\u201318 (2019).","DOI":"10.1128\/AAC.01855-18"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Gatti M, Rinaldi M, Potena L, Salvaterra E, Morelli MC, Giannella M, Viale P, Pea F. Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? <i>Transpl. Infect. Dis.<\/i>, <b>25<\/b>, e14107 (2023).","DOI":"10.1111\/tid.14107"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) van der Wekken-Pas LC, Tott\u00e9 J, Lunel FV, van Zuilen A, van Luin M. Therapeutic drug monitoring of ganciclovir in cytomegalovirus-infected patients with solid organ transplants and its correlation to efficacy and toxicity. <i>Ther. Drug Monit.<\/i>, <b>45<\/b>, 533\u2013538 (2023).","DOI":"10.1097\/FTD.0000000000001054"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Galar A, Valerio M, Catal\u00e1n P, Garc\u00eda-Gonz\u00e1lez X, Burillo A, Fern\u00e1ndez-Cruz A, Zatar\u00e1in E, Sousa-Casasnovas I, Anaya F, Rodr\u00edguez-Ferrero ML, Mu\u00f1oz P, Bouza E. Valganciclovir-ganciclovir use and systematic therapeutic drug monitoring. An invitation to antiviral stewardship. <i>Antibiotics<\/i>, <b>10<\/b>, 77 (2021).","DOI":"10.3390\/antibiotics10010077"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) M\u00e4rtson AG, Edwina AE, Burgerhof JGM, Berger SP, de Joode A, Damman K, Verschuuren EAM, Blokzijl H, Bakker M, Span LF, van der Werf TS, Touw DJ, Sturkenboom MGG, Knoester M, Alffenaar JWC. Ganciclovir therapeutic drug monitoring in transplant recipients. <i>J. Antimicrob. Chemother.<\/i>, <b>76<\/b>, 2356\u20132363 (2021).","DOI":"10.1093\/jac\/dkab195"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Katada Y, Nakagawa S, Nagao M, Umemura K, Itohara K, Nishikawa A, Hashi S, Katsube Y, Hira D, Ohsumi A, Nakajima D, Date H, Terada T. Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis. <i>Transpl. Infect. Dis.<\/i>, <b>25<\/b>, e14141 (2023).","DOI":"10.1111\/tid.14141"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Koloskoff K, Franck B, Benito S, Welzel J, Autmizguine J, Theoret Y, Briand A, Ovetchkine P, Woillard JB. Pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulations to predict cytomegalovirus viral load in pediatric transplant recipients treated with (val)ganciclovir. <i>Clin. Pharmacokinet.<\/i>, <b>64<\/b>, 1061\u20131069 (2025).","DOI":"10.1007\/s40262-025-01526-z"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Cojutti PG, Heffernan AJ, T\u00e4ngd\u00e9n T, Della Siega P, Tascini C, Roberts JA, Pea F. Population pharmacokinetic and pharmacodynamic analysis of valganciclovir for optimizing preemptive therapy of cytomegalovirus infections in kidney transplant recipients. <i>Antimicrob. Agents Chemother.<\/i>, <b>67<\/b>, e01665\u201322 (2023).","DOI":"10.1128\/aac.01665-22"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) M\u00e4rtson AG, Sturkenboom MGG, Knoester M, van der Werf TS, Alffenaar JWC, Hope W. Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. <i>J. Antimicrob. Chemother.<\/i>, <b>77<\/b>, 466\u2013473 (2022).","DOI":"10.1093\/jac\/dkab419"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>5<\/b>, 1003\u20131009 (2010).","DOI":"10.2215\/CJN.06870909"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. <i>Am. J. Kidney Dis.<\/i>, <b>53<\/b>, 982\u2013992 (2009).","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"23","unstructured":"23) The Japanese Society for Hematopoietic Cell Transplantation. \u201cHematopoietic cell transplantation guidelines: cytomegalovirus infection (3rd edition).\u201d The Japanese Society for Hematopoietic Cell Transplantation; 2014: \u2039https:\/\/www.jstct.or.jp\/uploads\/files\/guideline\/03m_cmv.pdf\u203a, accessed 2 February, 2026."},{"key":"24","unstructured":"24) The Japanese Society for Hematopoietic Cell Transplantation. \u201cHematopoietic cell transplantation guidelines: cytomegalovirus infection (4th edition). JSHCT Monograph Vol 57.\u201d The Japan Society for Hematopoietic Cell Transplantation; 2018: \u2039https:\/\/www.jstct.or.jp\/uploads\/files\/guideline\/01_03_01_cmv04.pdf\u203a, accessed 2 February, 2026."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Roongpairoj Y, Uchida M, Yamazaki S, Sawada M, Suzuki T, Kawasaki K, Niibe Y, Goto Y, Suzuki T, Ishikawa M, Ishii I. Contribution of adsorption and hematocrit levels to ganciclovir clearance in an <i>in vitro<\/i> continuous hemodiafiltration model. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 1396\u20131404 (2024).","DOI":"10.1248\/bpb.b24-00268"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Selby PR, Heffernan AJ, Yeung D, Warner MS, Peake SL, Hahn U, Wallis SC, McWhinney B, Ungerer JPJ, Shakib S, Roberts JA. Population pharmacokinetics of ganciclovir in allogeneic hematopoietic stem cell transplant patients. <i>Antimicrob. Agents Chemother.<\/i>, <b>67<\/b>, e01550\u201322 (2023).","DOI":"10.1128\/aac.01550-22"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Cald\u00e9s A, Colom H, Armendariz Y, Garrido MJ, Troconiz IF, Gil-Vernet S, Lloberas N, Pou L, Peraire C, Griny\u00f3 JM. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. <i>Antimicrob. Agents Chemother.<\/i>, <b>53<\/b>, 4816\u20134824 (2009).","DOI":"10.1128\/AAC.00085-09"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Chen B, Hu SS, Rui WB, An HM, Zhai XH, Wang XH, Lu JQ, Shao K, Zhou PJ. Population pharmacokinetics and bayesian estimation of the area under the concentration-time curve for ganciclovir in adult Chinese renal allograft recipients after valganciclovir administration. <i>J. Clin. Pharmacol.<\/i>, <b>61<\/b>, 328\u2013338 (2021).","DOI":"10.1002\/jcph.1735"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Horvatits T, Kitzberger R, Drolz A, Zauner C, J\u00e4ger W, B\u00f6hmdorfer M, Kraff S, Fritsch A, Thalhammer F, Fuhrmann V, Schenk P. Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. <i>Antimicrob. Agents Chemother.<\/i>, <b>58<\/b>, 94\u2013101 (2014).","DOI":"10.1128\/AAC.00892-13"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Mori T, Okamoto S, Watanabe R, Yajima T, Iwao Y, Yamazaki R, Nakazato T, Sato N, Iguchi T, Nagayama H, Takayama N, Hibi T, Ikeda Y. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplant.<\/i>, <b>29<\/b>, 777\u2013782 (2002).","DOI":"10.1038\/sj.bmt.1703542"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kanda Y, Yamashita T, Mori T, Ito T, Tajika K, Mori S, Sakura T, Hara M, Mitani K, Kurokawa M, Akashi K, Harada M. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. <i>Bone Marrow Transplant.<\/i>, <b>45<\/b>, 1325\u20131332 (2010).","DOI":"10.1038\/bmt.2009.337"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Morinaga Y, Sawayama Y, Hidaka M, Mori S, Taguchi J, Takatsuki M, Eguchi S, Miyazaki Y, Yanagihara K. Diagnostic utility of cytomegalovirus nucleic acid testing during antigenemia-guided cytomegalovirus monitoring after hematopoietic stem cell transplantation or liver transplantation. <i>Tohoku J. Exp. Med.<\/i>, <b>247<\/b>, 179\u2013187 (2019).","DOI":"10.1620\/tjem.247.179"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Halfon P, Berger P, Khiri H, Martineau A, P\u00e9naranda G, Merlin M, Faucher C. Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation. <i>J. Med. Virol.<\/i>, <b>83<\/b>, 490\u2013495 (2011).","DOI":"10.1002\/jmv.21996"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Ishii K, Onishi Y, Miyamura N, Fukuhara N, Ishizawa K, Nakanishi M, Ohnaka S, Miyasaka T, Kanno E, Kawakami K, Harigae H, Kaku M. Development and evaluation of a quantitative assay detecting cytomegalovirus transcripts for preemptive therapy in allogeneic hematopoietic stem cell transplant recipients. <i>J. Med. Virol.<\/i>, <b>89<\/b>, 1265\u20131273 (2017).","DOI":"10.1002\/jmv.24775"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kanda Y, Mineishi S, Saito T, Saito A, Ohnishi M, Niiya H, Chizuka A, Nakai K, Takeuchi T, Matsubara H, Makimoto A, Tanosaki R, Kunitoh H, Tobinai K, Takaue Y. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. <i>Transplantation<\/i>, <b>73<\/b>, 568\u2013572 (2002).","DOI":"10.1097\/00007890-200202270-00015"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Tornatore KM, Garey KW, Saigal N, Reed K, Murray B, Ingalls E, DiFrancesco R, Forrest A, Morse G, Venuto R. Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. <i>Clin. Transplant.<\/i>, <b>15<\/b>, 297\u2013308 (2001).","DOI":"10.1034\/j.1399-0012.2001.150501.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O\u2019Grady J, Robinson C, To Z, Wren K, Banken L, Buhles W, Brown F. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. <i>Antimicrob. Agents Chemother.<\/i>, <b>44<\/b>, 2811\u20132815 (2000).","DOI":"10.1128\/AAC.44.10.2811-2815.2000"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Venton G, Crocchiolo R, F\u00fcrst S, Granata A, Oudin C, Faucher C, Coso D, Bouabdallah R, Berger P, Vey N, Ladaique P, Chabannon C, le Merlin M, Blaise D, El-Cheikh J. Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. <i>Clin. Microbiol. Infect.<\/i>, <b>20<\/b>, 160\u2013166 (2014).","DOI":"10.1111\/1469-0691.12222"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/8\/49_b26-00209\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:20:53Z","timestamp":1787372453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/8\/49_b26-00209\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00209","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"article-number":"b26-00209"}}